HC Wainwright raises Nuvectis Pharma price target to $13
HC Wainwright & Co. analyst Joseph Pantginis maintained a Buy rating on Nuvectis Pharma and raised the price target to $13 from $10.
*this image is generated using AI for illustrative purposes only.
HC Wainwright & Co. analyst Joseph Pantginis has maintained a Buy rating on Nuvectis Pharma, citing an updated valuation. The firm raised its price target for the stock to $13, an increase from the previous target of $10.
The adjustment reflects the analyst's confidence in the company's prospects. Nuvectis Pharma trades on the NASDAQ under the ticker symbol NVCT.
What specific factors drove the 30% increase in the price target for Nuvectis Pharma?
How might this rating upgrade influence investor sentiment and trading volume for NVCT in the short term?
What upcoming clinical milestones or catalysts could further validate the raised price target?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
